Literature DB >> 23490418

YKL-40 in hemodialyzed patients with and without cardiovascular complications - the enhancement by the coexistence of the seropositivity against hepatitis C virus infection.

Krystyna Pawlak1, Dariusz Rozkiewicz, Michal Mysliwiec, Dariusz Pawlak.   

Abstract

BACKGROUND: YKL-40 is a new biomarker of inflammation, which is expressed by several cell types of the immune system. The aim of the present study was to evaluate plasma YKL-40 levels in hemodialysis (HD) patients and to establish its potential role as a new inflammatory biomarker of cardiovascular disease (CVD) in this population.
METHODS: YKL-40 and two other inflammatory markers: high sensitivity C-reactive protein (hsCRP) and neopterin levels were measured in 70 HD patients both with and without CVD and in 38 healthy controls.
RESULTS: Median YKL-40, hsCRP and neopterin levels were significantly elevated in HD patients, particularly those with CVD, compared to controls. YKL-40 was no associated with hsCRP, but it is strongly and independently associated with plasma neopterin levels in HD patients. The coexistence of the seropositivity against hepatitis C virus (anti-HCV) infection increased both YKL-40 and neopterin levels in these patients. This effect was particularly seen in subjects with CVD. Moreover, high neopterin levels were exclusively associated with anti-HCV seropositivity, whereas hsCRP values were only associated with the presence of CVD.
CONCLUSIONS: This study indicated for the first time that plasma YKL-40 level is increased in HD patients, especially in those with CVD, and it is independently associated with neopterin - an biomarker of monocyte/macrophage activation. There was no association between YKL-40 and hsCRP, the common indicator of an inflammatory state. Moreover, the coexistence of anti-HCV seropositivity had an important impact on plasma YKL-40 levels in HD patients particularly those with cardiovascular complications.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23490418     DOI: 10.1016/j.cyto.2013.02.014

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

1.  A Heparin Binding Motif Rich in Arginine and Lysine is the Functional Domain of YKL-40.

Authors:  Nipaporn Ngernyuang; Wei Yan; Lawrence M Schwartz; Dennis Oh; Ying-Bin Liu; Hongzhuan Chen; Rong Shao
Journal:  Neoplasia       Date:  2017-12-20       Impact factor: 5.715

2.  Glycoprotein YKL-40 Is Elevated and Predicts Disease Severity in Puumala Hantavirus Infection.

Authors:  Tuula K Outinen; Paula Mantula; Pia Jaatinen; Mari Hämäläinen; Eeva Moilanen; Antti Vaheri; Heini Huhtala; Satu Mäkelä; Jukka Mustonen
Journal:  Viruses       Date:  2019-08-21       Impact factor: 5.048

3.  The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients.

Authors:  Almudena Vega; Maria Dolores Sanchez-Niño; Alberto Ortiz; Soraya Abad; Nicolás Macías; Inés Aragoncillo; Alba Santos; Ana García-Prieto; Esther Torres; Andrés Hernández; Luis Sánchez-Cámara; Esther Hurtado; Lara Valiño-Rivas; José Luño
Journal:  Clin Kidney J       Date:  2019-05-20

Review 4.  Large uremic toxins: an unsolved problem in end-stage kidney disease.

Authors:  Martin J Wolley; Colin A Hutchison
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.